Kulemzin S V, Kuznetsova V V, Mamonkin M, Taranin A V, Gorchakov A A
Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, 630090 Russia.
Center for Cell and Gene Therapy, Baylor College of Medicine Texas Children's Hospital and Houston Methodist Hospital, Houston, USA.
Mol Biol (Mosk). 2017 Mar-Apr;51(2):274-287. doi: 10.7868/S0026898417020148.
Early results from clinical trials of autologous chimeric antigen receptor (CAR)-expressing T cells for the therapy of B-cell malignancies have encouraged extending the potency of this therapy to other cancers. However, the success of using CAR T-cells to treat patients with solid tumors has been limited. In this review, we summarize current knowledge on the design and applications of CARs for the targeted therapy of cancer. We describe existing issues that limit the widespread application of CAR T cells and discuss the optimization steps needed to further improve safety and efficacy of this therapeutic platform.
用于治疗B细胞恶性肿瘤的自体嵌合抗原受体（CAR）表达T细胞的临床试验早期结果，促使人们将这种疗法的效力扩展至其他癌症。然而，使用CAR T细胞治疗实体瘤患者的成效有限。在本综述中，我们总结了目前关于CAR用于癌症靶向治疗的设计和应用的知识。我们描述了限制CAR T细胞广泛应用的现有问题，并讨论了进一步提高该治疗平台安全性和疗效所需的优化步骤。
